Cerus Stock Price, News & Analysis (NASDAQ:CERS)

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares.
View CERS analyst ratings or view top-rated stocks.

3 brokers have issued 12 month price objectives for Cerus' shares. Their CERS share price targets range from $3.00 to $3.75. On average, they predict the company's stock price to reach $3.38 in the next year. This suggests a possible upside of 104.5% from the stock's current price.
View analysts price targets for CERS or view top-rated stocks among Wall Street analysts.

Cerus' stock was trading at $3.65 at the beginning of the year. Since then, CERS shares have decreased by 54.8% and is now trading at $1.65.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CERS earnings forecast.

Cerus Co. (NASDAQ:CERS) released its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.02. The biotechnology company had revenue of $39.77 million for the quarter, compared to analyst estimates of $40.90 million. Cerus had a negative net margin of 32.40% and a negative trailing twelve-month return on equity of 84.23%.

ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ARK Innovation ETF (ARKK).

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Cerus' stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.10%), Sumitomo Mitsui Trust Holdings Inc. (4.38%), Senvest Management LLC (4.01%), Sepio Capital LP (1.93%), Northern Trust Corp (1.02%) and Walleye Capital LLC (1.00%). Insiders that own company stock include Ann Lucena, Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Eric Bjerkholt, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends.

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.